Vivantes MVZ GmbH — Clinical Trial Site

13 Registered trials

5 Currently recruiting

Organisation

Vivantes MVZ GmbH

Location

Berlin, Germany

Identifier

ORG-100048712

Address

Landsberger Allee 49, Friedrichshain, 10249, Germany

Departments

"Klinik fuer Innere Medizin Haematologie und Onkologie"
Brustzentrum, Klinikum Am Urban
Haematologie und Onkologie
Haematologie, Onkologie und Palliativmedizin
Hematology
Hematology and Oncology
Klinik fuer Innere Medizin
Klinik für Hämatologie und Onkologie
Klinik für Hämatologie, Onkologie und Palliativmedizin
Klinik für Innere Medizin
Klinik für Innere Medizin - Angiologie und Hämostaseologie
Klinik für Innere Medizin – Hämatologie und Onkologie und Palliativmedizin
Klinik für Innere Medizin, Hämatologie, Onkologie und Palliativmedizin
RadioOnkologie

Clinical trials at this site (13)

Search interface

Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 NPM1-m and KMT2A-r Acute Myeloid Leukemia 5 2026-03-19
ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesopha… Recruiting

2025-522718-22-00 Gastroesophageal Adenocarcinoma 4 2025-12-16
A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad… Recruiting

2023-505077-32-00 Locally-advanced or metastatic non-squamous non-small c 5 2025-01-28
Early Stage Follicular LymphOma and RadioTherapy PLUS anti-CD20 Antibody Recruiting

2023-509278-41-00 Early Stage Follicular LymphOma 5 2022-07-04
A trial to learn how well AZD0901 works and how safe it is compared to standard cancer treatments in adults with advanced and metastatic gas… Ended

2023-508276-11-00 Gastric cancer, Advanced/Metastatic Gastric cancer, Gas 5 2025-01-17
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C… Ended

2023-505552-22-00 Stage I-III Triple-negative Breast Cancer with residual 5 2023-02-24
Protocol Title: Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VI… Ended

2024-512075-12-00 hemophilia A 5 2021-06-14
A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended

2023-509358-72-00 Diffuse large B-cell lymphoma 5 2020-11-23
Reduced intensity radio-chemotherapy for stage IIA/B seminoma Ended

2023-509663-24-00 Stage IIA/B seminoma 4 2020-08-20
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15
C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People … Ended

2022-502822-41-00 Relapsed/Refractory Diffuse Large B Cell Lymphoma 9